 |
인쇄하기
취소
|
Celgene’s cancer pill to increase global sales
Celgene Corp. is increasing global sales for its best-selling cancer pill Revlimid (lenalidomide) on new data that may convince doctors to choose the drug as a first option.
Revlimid generated $970 million in sales last year as a back-up therapy for patients with multiple myeloma who don’t respond to other options.
Market observers said that although the first-line setting is currently do...
Revlimid generated $970 million in sales last year as a back-up therapy for patients with multiple myeloma who don’t respond to other options.
Market observers said that although the first-line setting is currently do...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.